IMMUNOCYT
            <sup>1</sup>
            : A NEW TOOL FOR DETECTING TRANSITIONAL CELL CANCER OF THE URINARY TRACT

Mian, Christine; Pycha, Armin; Wiener, H.; Haitel, Andrea; Lodde, Michele; Marberger, Michael

doi:10.1016/s0022-5347(05)68934-3

Cited by 172 publications

(105 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The combination of ImmunoCyt/uCytt with cytology may also help to detect nonvisible HG cancers, which are often missed by the cystoscopist. In our study, as in others, 7,14,20 all carcinomas in situ were found by combining cytology and ImmunoCyt/uCytt, while 50% had either negative or suspicious cytology. Reactive urothelial cells show mild abnormalities that are shared by LG neoplastic cells and require considerable screening time from pathologists and cytologists.…”

Section: Discussionsupporting

confidence: 87%

“…Indeed, in most studies, the sensitivity of ImmunoCyt/uCytt combined with cytology exceeds 80% when a threshold of 1 red or 1 green fluorescent cell is used. 6,7,[11][12][13][14] Our sensitivity of 84% means that, if a tumor is present, it would most likely be detected by the test. Therefore, if the test is positive, a cystoscopy should be performed and, if no tumor is seen, a tumor from the upper urinary tract should be suspected and ruled out.…”

Section: Discussionmentioning

confidence: 99%

“…Our negative predictive value of 95% is comparable to other studies which ranged from 81 15 to 97%. 7 Such a high-negative predictive value means that, if the test is negative, patients undergoing a standard cystoscopy protocol for a history of bladder cancer are unlikely to have recurrent bladder tumor and that the next control cystoscopy may be postponed. In young patients investigated for urinary symptoms, presence of a bladder tumor is unlikely with a negative test and cystoscopy might be omitted.…”

Section: Discussionmentioning

confidence: 99%

“…8 19A211, labelled with Texas red, recognizes a high molecular form of carcinoembryonic antigen (CEA) and is expressed by 90% of Ta-T1 tumors. 8 Since the preliminary study by Mian et al, 7 few additional studies have been published on the clinical usefulness of ImmunoCyt/uCytt. This study was aimed at evaluating the clinical value of ImmunoCyt/uCytt in the diagnosis and follow-up of patients with urothelial carcinoma, and in cases with atypias suspicious for malignancy by cytology.…”

mentioning

confidence: 99%

See 3 more Smart Citations

ImmunoCyt/uCyt+™ improves the sensitivity of urine cytology in patients followed for urothelial carcinoma

et al. 2005

View full text Add to dashboard Cite

ImmunoCyt/uCytt is a fluorescent test combining three monoclonal antibodies. In this study, it has been tested as a complement to cytology in the detection of urothelial carcinoma in urine. It has been performed simultaneously with standard cytology and cystoscopy on 870 urine analyses from one hospital. In 136 cases, one or more bladder tumors were found. Overall sensitivity of cytology, ImmunoCyt/uCytt and combined analyses reached 29, 74 and 84%, respectively, and overall specificity was 98, 62 and 61%. The negative predictive value of cytology, ImmunoCyt/uCytt and both analyses was 88, 93 and 95%, respectively, and the positive predictive value was 70, 26 and 29%. The sensitivity of cytology for low malignant potential neoplasms, low-and high-grade papillary carcinomas was 6, 18 and 53%, while it reached 71, 79 and 93% when combined with ImmunoCyt/uCytt. The sensitivity of cytology for stages Ta, T1, T2 and over and Tis tumors was12, 67, 47 and 50%, while it reached 78, 83, 79 and 100% when combined with ImmunoCyt/uCytt. In the absence of tumor on cystoscopy but with positive ImmunoCyt/uCytt, 18% of patients developed a tumor, 2-6 months later. Of the 109 cases diagnosed as suspicious for malignancy by cytology, a tumor was present in 30 cases and ImmunoCyt/uCytt was positive in 22 (73%) of them. In conclusion, ImmunoCyt/uCytt may be used to postpone cystoscopies in patients followed for bladder cancer and may help to save cytologist and pathologist screening Keywords: urothelial carcinoma; cytology; ImmunoCyt/uCytt; immunofluorescence; urinary bladder; recurrence Superficial bladder cancers are defined as tumors limited to the mucosa (Tis, Ta) or invading into the lamina propria (T1), without muscle invasion. 1 They represent more than 80% of urothelial carcinomas and more than 50% will recur. 1-3 Patients with bladder cancer are followed with regular cytologies and cystoscopies. Cytology is very specific but this test is limited by its low sensitivity ranging from 16 to 60%. 4 Cytology is most useful at detecting highgrade (HG) cancer, whereas its sensitivity for lowgrade (LG) urothelial tumors is low and merely reaches 17%. 4 Furthermore, criteria used in urinary cytology to detect tumor cells are largely subjective and the ability to detect cancer cells is dependent on the experience of cytologists or pathologists. For instance, atypical cells and papillary aggregates may be found in either reactive or neoplastic conditions. 5 Furthermore, LG urothelial carcinomas do not always exfoliate in aggregates and the cell characteristics are often so subtle that they might not be recognizable even by an experienced cytologist. 5 Standard practice in the follow-up of patients with bladder cancer requires cystoscopies at regular intervals, but this technique is invasive, costly and causes discomfort to the patient. It is thus estimated that by improving the sensitivity of cytology, fewer follow-up cystoscopies would be needed. Furthermore, improved sensitivity would help cytologists and pathologists to save time c...

show abstract

Section: Discussionsupporting

confidence: 87%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

ImmunoCyt/uCyt+™ improves the sensitivity of urine cytology in patients followed for urothelial carcinoma

et al. 2005

View full text Add to dashboard Cite

show abstract

“…7 Recently, 2 new methods for urine-bound detection of bladder cancer, that is, urinary hyaluronic acid and hyaluronidase levels, and the immunocytochemical test, Immunocyt, were introduced achieving high sensitivity and specificity levels of more than 80%. 24,25 In conclusion, MSA offers high sensitivity levels of up to 84.5% for the detection of bladder cancer-specific serum DNA alterations and 72% for the detection of urine sediment alterations. Of a panel of 17 microsatellite markers we could identify 5 from the chromosomal regions 8p, 9p and 9q that offered the highest sensitivity in diagnosing TCC-specific alterations in serum and urine of cancer patients.…”

Section: Discussionmentioning

confidence: 89%

Serum DNA and urine DNA alterations of urinary transitional cell bladder carcinoma detected by fluorescent microsatellite analysis

et al. 2001

View full text Add to dashboard Cite

There are no reliable serologic tumor markers for transitional cell carcinoma (TCC) of the urinary bladder and noninvasive urine investigations are inadequate. We used fluorescent microsatellite analysis (MSA) to detect serum DNA and urine-sediment DNA alterations in patients with bladder cancer and prospectively collected fresh tumor, peripheral blood, serum and spontaneous urine specimens from 39 consecutive patients treated for TCC of the bladder to obtain the corresponding DNA. Urinary bladder cancer accounts for approximately 3% of all newly diagnosed malignancies in Western countries. In contrast to most other tumors, bladder carcinoma offers the opportunity of noninvasive diagnosis via urinary cytology. Yet a reliable serologic tumor marker is not available. Follow-up for bladder carcinoma is demanding and time consuming, as most bladder cancers at diagnosis grow superficially and will recur in 70% of cases within 2 years of primary treatment. 1 The intensive follow-up for transitional cell carcinoma (TCC) of the bladder still relies on invasive diagnostic measures such as cystoscopy and bladder washings for urine cytology. Cytology has a low sensitivity in the diagnosis of well-differentiated papillary tumors. A reliable serologic marker and a highly sensitive urinary investigation could reduce the requirement and frequency of invasive procedures during follow-up.In recent studies molecular techniques have proved applicable for the detection of smallest amounts of free circulating tumor DNA in serum and plasma of cancer patients. 2,3 Using microsatellite analysis (MSA) Goessl et al. 3 identified plasma DNA alterations in 63% of patients with renal cell carcinoma. In recent studies MSA was also used to detect tumor-specific DNA alterations in urine sediment samples of patients with TCC of the urinary bladder. 4,5 In a pilot study Steiner et al. 4 achieved a sensitivity of 90% for the urinary cancer diagnosis with radiolabeled microsatellite markers. In contrast to cytology, this method is independent of tumor histomorphologic features, and thus offers high sensitivity in well-differentiated tumors. This molecular genetic assay, not previously looked at in TCC, could reliably identify tumor-specific alterations in the serum of patients and its use in follow-up after radical surgical therapy could lead to early tumor recurrence identification. In the case of superficial bladder cancers, MSA may be helpful in diagnosing local recurrence without the need for invasive measures dependent on morphologic tumor features. We therefore used MSA with 17 highly polymorphic fluorescently labeled microsatellite markers from the chromosomal regions 5q, 8p, 9p, 9q, 13q, 14q, 17p, 17q and 20q to detect serum DNA and sediment-DNA alterations from spontaneous urine samples of 39 consecutive patients treated for TCC of the urinary bladder, to evaluate the sensitivity of the method in the serologic and urinary diagnosis of bladder TCC. MATERIAL AND METHODS Tumor, blood and urine samplingIn 1999, we prospectively collected preo...

show abstract

Surveillance for Recurrent Bladder Cancer Using a Point-of-Care Proteomic Assay

Grossman

Soloway

Messing

et al. 2006

JAMA

236

View full text Add to dashboard Cite

show abstract

IMMUNOCYT ¹ : A NEW TOOL FOR DETECTING TRANSITIONAL CELL CANCER OF THE URINARY TRACT

Abstract: Immunocyt is a noninvasive, highly sensitive test for detecting transitional cell carcinoma of all grades and stages. When combined with conventional urinary cytology, it may replace cystoscopy in select patients, especially in followup protocols of low grade transitional cell carcinoma.

Cited by 172 publications

References 8 publications

ImmunoCyt/uCyt+™ improves the sensitivity of urine cytology in patients followed for urothelial carcinoma

ImmunoCyt/uCyt+™ improves the sensitivity of urine cytology in patients followed for urothelial carcinoma

Serum DNA and urine DNA alterations of urinary transitional cell bladder carcinoma detected by fluorescent microsatellite analysis

Surveillance for Recurrent Bladder Cancer Using a Point-of-Care Proteomic Assay

Contact Info

Product

Resources

About

IMMUNOCYT 1 : A NEW TOOL FOR DETECTING TRANSITIONAL CELL CANCER OF THE URINARY TRACT

Abstract: Immunocyt is a noninvasive, highly sensitive test for detecting transitional cell carcinoma of all grades and stages. When combined with conventional urinary cytology, it may replace cystoscopy in select patients, especially in followup protocols of low grade transitional cell carcinoma.

Cited by 172 publications

References 8 publications

ImmunoCyt/uCyt+™ improves the sensitivity of urine cytology in patients followed for urothelial carcinoma

ImmunoCyt/uCyt+™ improves the sensitivity of urine cytology in patients followed for urothelial carcinoma

Serum DNA and urine DNA alterations of urinary transitional cell bladder carcinoma detected by fluorescent microsatellite analysis

Surveillance for Recurrent Bladder Cancer Using a Point-of-Care Proteomic Assay

Contact Info

Product

Resources

About

IMMUNOCYT ¹ : A NEW TOOL FOR DETECTING TRANSITIONAL CELL CANCER OF THE URINARY TRACT